Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma

Hutajulu, Susanna Hilda; Kurnianda, Johan; Bing Tan, I.; Middeldorp, Jaap M.
September 2014
Therapeutics & Clinical Risk Management;2014, Vol. 10, p721
Academic Journal
Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein-Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein-Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC.


Related Articles

  • Intensity-modulated radiotherapy with simultaneous modulated accelerated boost technique and chemotherapy in patients with nasopharyngeal carcinoma. Fareed, Muhammad M.; AlAmro, Abdullah S.; Bayoumi, Yasser; Tunio, Mutahir A.; Ismail, Abdul S.; Akasha, Rashad; Mubasher, Mohamed; Asiri, Mushabbab A. l. // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: To present our experience of intensity-modulated radiotherapy (IMRT) with simultaneous modulated accelerated radiotherapy (SMART) boost technique in patients with nasopharyngeal carcinoma (NPC). Methods: Sixty eight patients of NPC were treated between April 2006 and December 2011...

  • Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. Yunbao Pan; Mengyao Wang; Xianzhang Bu; Yinglin Zuo; Sumei Wang; Dujuan Wang; Qing Liu; Bojin Su; Tao Xu; Chunhua Wang; Claret, Francois X; Huiling Yang // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignancy that is most common in East Asia, Africa, and Alaska. Radiotherapy is the main treatment option; unfortunately, disease response to concurrent radiotherapy and chemotherapy varies among patients with NPC,...

  • Current and emerging treatment options for nasopharyngeal carcinoma. Spratt, Daniel E.; Nancy Lee // OncoTargets & Therapy;2012 Part 2, Vol. 5, p297 

    In this article, we focus on the current and emerging treatments in nasopharyngeal cancer (NPC). A detailed evolution of the current standard of care, and new techniques and treatment options will be reviewed. Intergroup 0099 established the role for chemoradiotherapy (chemo-RT) in the treatment...

  • Viral double whammy triggers cancers. Weuthrich, Bernice // New Scientist;8/5/95, Vol. 147 Issue 1989, p17 

    Reports a discovery by US researchers of nasopharyngeal cancer being caused by Epstein-Barr virus (EBV). Chances that infection of Southern Chinese population with the disease may be due to genetic and dietary factors; Research on EBV virus and latent membrane protein 1 (LMP1); Role of EBV in...

  • Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment. Murono, Shigeyuki; Kondo, Satoru; Wakisaka, Naohiro; Yoshizaki, Tomokazu // Current Cancer Therapy Reviews;2009, Vol. 5 Issue 3, p170 

    Nasopharyngeal carcinoma (NPC) is a highly invasive and metastatic tumor, which is universally associated with Epstein-Barr virus (EBV). Clinically, radiotherapy, but not surgery, is usually performed for the treatment of NPC because of the deep and complex location of the tumor. Previous...

  • Nasopharyngeal carcinoma. Chan, A. T. C. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii308 

    With the improvement in local control achieved by more precise imaging and radiotherapy, the predominant mode of failure for nasopharyngeal carcinoma is distant metastases. Concurrent cisplatin–radiotherapy with or without adjuvant chemotherapy is the standard treatment approach for...

  • Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Xiao, L; Hu, Z-y; Dong, X; Tan, Z; Li, W; Tang, M; Chen, L; Yang, L; Tao, Y; Jiang, Y; Li, J; Yi, B; Li, B; Fan, S; You, S; Deng, X; Hu, F; Feng, L; Bode, A M; Dong, Z // Oncogene;9/11/2014, Vol. 33 Issue 37, p4568 

    Our goal in this work was to illustrate the Epstein-Barr virus (EBV)-modulated global biochemical profile and provide a novel metabolism-related target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC). We used a metabolomics approach to investigate EBV-modulated metabolic...

  • Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. Chia, Whay-Kuang; Teo, Marissa; Wang, Who-Whong; Lee, Bernett; Ang, Soo-Fan; Tai, Wai-Meng; Chee, Chit-Lai; Ng, Joanna; Kan, Rebecca; Lim, Wan-Teck; Tan, Sze-Huey; Ong, Whee-Sze; Cheung, Yin-Bun; Tan, Eng-Huat; Connolly, John E; Gottschalk, Stephen; Toh, Han-Chong // Molecular Therapy;Jan2014, Vol. 22 Issue 1, p132 

    The outcomes for patients with metastatic or locally recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) remain poor. Adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes (EBV-CTLs) has proven clinical efficacy, but it has never been evaluated in the first-line...

  • Central nervous system involvement in Hodgkin's lymphoma. Galán, L.; Sánchez, A.; Cantos, B.; Provencio, M. // Medical Oncology;Dec2011, Vol. 28, p505 

    Central nervous system involvement in Hodgkin´s lymphoma is extremely rare. We report three cases who had a relapse from the disease involving CNS. The most frequent causes are skull contiguity, meningeal invasion and via the hematogenous route. It is frequent that the association between...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics